Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984

Key clinical point: The rate of development of rheumatoid arthritis (RA) was lower in patients with diabetes who used vs did not use sulfonylureas or biguanides, with biguanides appearing to have a more rapid and sulfonylureas having a longer effect in lowering RA incidence.

Major finding: Among patients with diabetes, sulfonylureas or biguanides users vs nonusers were at a reduced risk of developing RA (adjusted hazard ratio 0.73; 95% CI 0.60-0.90), with the risk being lower in those prescribed biguanides for >180 days within 1 year (adjusted odds ratio [aOR] 0.72; 95% CI 0.53-0.99) and those prescribed sulfonylureas for >365 days within 3 years (aOR 0.62; 95% CI 0.46-0.84) of the first RA visit.

Study details: Findings are from a cohort study including 94,141 patients with diabetes, of which 494 patients developed RA and were age- and sex-matched with 988 patients who did not develop RA.

Disclosures: This study was supported by Chung Shan Medical University Hospital, Taiwan, Chang Gung Memorial Hospital, and others. The authors declared no conflicts of interest.

Source: Su YJ et al. Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study. Front Med (Lausanne). 2022;9:934184 (Jul 27). Doi: 10.3389/fmed.2022.934184

Key clinical point: The rate of development of rheumatoid arthritis (RA) was lower in patients with diabetes who used vs did not use sulfonylureas or biguanides, with biguanides appearing to have a more rapid and sulfonylureas having a longer effect in lowering RA incidence.

Major finding: Among patients with diabetes, sulfonylureas or biguanides users vs nonusers were at a reduced risk of developing RA (adjusted hazard ratio 0.73; 95% CI 0.60-0.90), with the risk being lower in those prescribed biguanides for >180 days within 1 year (adjusted odds ratio [aOR] 0.72; 95% CI 0.53-0.99) and those prescribed sulfonylureas for >365 days within 3 years (aOR 0.62; 95% CI 0.46-0.84) of the first RA visit.

Study details: Findings are from a cohort study including 94,141 patients with diabetes, of which 494 patients developed RA and were age- and sex-matched with 988 patients who did not develop RA.

Disclosures: This study was supported by Chung Shan Medical University Hospital, Taiwan, Chang Gung Memorial Hospital, and others. The authors declared no conflicts of interest.

Source: Su YJ et al. Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study. Front Med (Lausanne). 2022;9:934184 (Jul 27). Doi: 10.3389/fmed.2022.934184

Key clinical point: The rate of development of rheumatoid arthritis (RA) was lower in patients with diabetes who used vs did not use sulfonylureas or biguanides, with biguanides appearing to have a more rapid and sulfonylureas having a longer effect in lowering RA incidence.

Major finding: Among patients with diabetes, sulfonylureas or biguanides users vs nonusers were at a reduced risk of developing RA (adjusted hazard ratio 0.73; 95% CI 0.60-0.90), with the risk being lower in those prescribed biguanides for >180 days within 1 year (adjusted odds ratio [aOR] 0.72; 95% CI 0.53-0.99) and those prescribed sulfonylureas for >365 days within 3 years (aOR 0.62; 95% CI 0.46-0.84) of the first RA visit.

Study details: Findings are from a cohort study including 94,141 patients with diabetes, of which 494 patients developed RA and were age- and sex-matched with 988 patients who did not develop RA.

Disclosures: This study was supported by Chung Shan Medical University Hospital, Taiwan, Chang Gung Memorial Hospital, and others. The authors declared no conflicts of interest.

Source: Su YJ et al. Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study. Front Med (Lausanne). 2022;9:934184 (Jul 27). Doi: 10.3389/fmed.2022.934184

Key clinical point: A serum lipid profile rich in long chain n-3 and n-6 polyunsaturated fatty acids (PUFA) was independently associated with a lower 6-month disease activity in a cohort of patients with early rheumatoid arthritis (RA).

Major finding: At 6 months, the odds of having a 28-joint Disease Activity Score of ≥5.1 was significantly lower in patients in higher tertiles of n-3 PUFA (odds ratio for tertile 3 vs 1 [ORt] 0.49; 95% CI 0.25-0.97) and n-6 PUFA (ORt 0.51; 95% CI 0.28-0.95), with the association being independent of baseline C-reactive protein levels.

Study details: This was a longitudinal cohort study including 669 patients with early RA.

Disclosures: This study was supported by Sorbonne Paris Nord University. The authors declared no conflicts of interest.

Source: Sigaux J et al. Serum fatty acid profiles are associated with disease activity in early rheumatoid arthritis: Results from the ESPOIR cohort. Nutrients. 2022;14(14):2947 (Jul 19). Doi:  10.3390/nu14142947

Key clinical point: A serum lipid profile rich in long chain n-3 and n-6 polyunsaturated fatty acids (PUFA) was independently associated with a lower 6-month disease activity in a cohort of patients with early rheumatoid arthritis (RA).

Major finding: At 6 months, the odds of having a 28-joint Disease Activity Score of ≥5.1 was significantly lower in patients in higher tertiles of n-3 PUFA (odds ratio for tertile 3 vs 1 [ORt] 0.49; 95% CI 0.25-0.97) and n-6 PUFA (ORt 0.51; 95% CI 0.28-0.95), with the association being independent of baseline C-reactive protein levels.

Study details: This was a longitudinal cohort study including 669 patients with early RA.

Disclosures: This study was supported by Sorbonne Paris Nord University. The authors declared no conflicts of interest.

Source: Sigaux J et al. Serum fatty acid profiles are associated with disease activity in early rheumatoid arthritis: Results from the ESPOIR cohort. Nutrients. 2022;14(14):2947 (Jul 19). Doi:  10.3390/nu14142947

Key clinical point: A serum lipid profile rich in long chain n-3 and n-6 polyunsaturated fatty acids (PUFA) was independently associated with a lower 6-month disease activity in a cohort of patients with early rheumatoid arthritis (RA).

Major finding: At 6 months, the odds of having a 28-joint Disease Activity Score of ≥5.1 was significantly lower in patients in higher tertiles of n-3 PUFA (odds ratio for tertile 3 vs 1 [ORt] 0.49; 95% CI 0.25-0.97) and n-6 PUFA (ORt 0.51; 95% CI 0.28-0.95), with the association being independent of baseline C-reactive protein levels.

Study details: This was a longitudinal cohort study including 669 patients with early RA.

Disclosures: This study was supported by Sorbonne Paris Nord University. The authors declared no conflicts of interest.

Source: Sigaux J et al. Serum fatty acid profiles are associated with disease activity in early rheumatoid arthritis: Results from the ESPOIR cohort. Nutrients. 2022;14(14):2947 (Jul 19). Doi:  10.3390/nu14142947

Key clinical point: Patients with rheumatoid arthritis (RA) who were positive for anti-Sjögren's-syndrome-related antigen A (SSA) antibody were less responsive to initial methotrexate treatment compared with patients negative for anti-SSA antibody.

Major finding: At 6 months, a significantly lower proportion of patients in the anti-SSA antibody positive vs negative group achieved low disease activity based on the 28-joint Disease Activity Score-C-reactive protein (56.2% vs 75.8%; P  =  .03). Patients positive for anti-SSA antibody had a higher patient visual analogue score (median score 22 vs 19; P  =  .038) and use of nonsteroidal anti-inflammatory drugs (37.5% vs 18.0%; P  =  .018).

Study details: This was a retrospective cohort study including 210 methotrexate- or biologic disease-modifying antirheumatic drug-naive patients with RA who initiated methotrexate, of which 32 patients tested positive for anti-SSA antibody.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Waki D et al. Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study. PLoS One. 2022;17(7):e0271921 (Jul 22). Doi: 10.1371/journal.pone.0271921

Key clinical point: Patients with rheumatoid arthritis (RA) who were positive for anti-Sjögren's-syndrome-related antigen A (SSA) antibody were less responsive to initial methotrexate treatment compared with patients negative for anti-SSA antibody.

Major finding: At 6 months, a significantly lower proportion of patients in the anti-SSA antibody positive vs negative group achieved low disease activity based on the 28-joint Disease Activity Score-C-reactive protein (56.2% vs 75.8%; P  =  .03). Patients positive for anti-SSA antibody had a higher patient visual analogue score (median score 22 vs 19; P  =  .038) and use of nonsteroidal anti-inflammatory drugs (37.5% vs 18.0%; P  =  .018).

Study details: This was a retrospective cohort study including 210 methotrexate- or biologic disease-modifying antirheumatic drug-naive patients with RA who initiated methotrexate, of which 32 patients tested positive for anti-SSA antibody.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Waki D et al. Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study. PLoS One. 2022;17(7):e0271921 (Jul 22). Doi: 10.1371/journal.pone.0271921

Key clinical point: Patients with rheumatoid arthritis (RA) who were positive for anti-Sjögren's-syndrome-related antigen A (SSA) antibody were less responsive to initial methotrexate treatment compared with patients negative for anti-SSA antibody.

Major finding: At 6 months, a significantly lower proportion of patients in the anti-SSA antibody positive vs negative group achieved low disease activity based on the 28-joint Disease Activity Score-C-reactive protein (56.2% vs 75.8%; P  =  .03). Patients positive for anti-SSA antibody had a higher patient visual analogue score (median score 22 vs 19; P  =  .038) and use of nonsteroidal anti-inflammatory drugs (37.5% vs 18.0%; P  =  .018).

Study details: This was a retrospective cohort study including 210 methotrexate- or biologic disease-modifying antirheumatic drug-naive patients with RA who initiated methotrexate, of which 32 patients tested positive for anti-SSA antibody.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Waki D et al. Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study. PLoS One. 2022;17(7):e0271921 (Jul 22). Doi: 10.1371/journal.pone.0271921

Key clinical point: Patients with rheumatoid arthritis (RA) who had symptoms of clinically active RA and cardiovascular disease were at an increased risk for dementia.

Major finding: Apart from the universally recognized risk factors for dementia, such as older age at RA incidence, hypertension, depression, and anxiety, RA disease characteristics, such as the presence of rheumatoid nodules (adjusted hazard ratio [aHR] 1.76; 95% CI 1.05-2.95), large joint swellings (aHR 2.11; 95% CI 1.33-3.34), and any cardiovascular disease at anytime after RA incidence (aHR 2.25; 95% CI 1.38-3.66) were significantly associated with an increased risk for dementia.

Study details: This was a retrospective cohort study including 886 patients with incident RA and without prior dementia, of which 103 patients developed dementia during a median follow-up of 8.5 years.

Disclosures: This study was supported by the US National Institutes of Health, National Institute of Aging, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. M Vassilaki reported receiving research funding and owning equity in various companies. MM Mielke reported receiving research grants or funding from and serving as a consultant for various sources.

Source: Kodishala C et al. Risk factors for dementia in patients with incident rheumatoid arthritis: A population-based cohort study. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.220200

Key clinical point: Patients with rheumatoid arthritis (RA) who had symptoms of clinically active RA and cardiovascular disease were at an increased risk for dementia.

Major finding: Apart from the universally recognized risk factors for dementia, such as older age at RA incidence, hypertension, depression, and anxiety, RA disease characteristics, such as the presence of rheumatoid nodules (adjusted hazard ratio [aHR] 1.76; 95% CI 1.05-2.95), large joint swellings (aHR 2.11; 95% CI 1.33-3.34), and any cardiovascular disease at anytime after RA incidence (aHR 2.25; 95% CI 1.38-3.66) were significantly associated with an increased risk for dementia.

Study details: This was a retrospective cohort study including 886 patients with incident RA and without prior dementia, of which 103 patients developed dementia during a median follow-up of 8.5 years.

Disclosures: This study was supported by the US National Institutes of Health, National Institute of Aging, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. M Vassilaki reported receiving research funding and owning equity in various companies. MM Mielke reported receiving research grants or funding from and serving as a consultant for various sources.

Source: Kodishala C et al. Risk factors for dementia in patients with incident rheumatoid arthritis: A population-based cohort study. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.220200

Key clinical point: Patients with rheumatoid arthritis (RA) who had symptoms of clinically active RA and cardiovascular disease were at an increased risk for dementia.

Major finding: Apart from the universally recognized risk factors for dementia, such as older age at RA incidence, hypertension, depression, and anxiety, RA disease characteristics, such as the presence of rheumatoid nodules (adjusted hazard ratio [aHR] 1.76; 95% CI 1.05-2.95), large joint swellings (aHR 2.11; 95% CI 1.33-3.34), and any cardiovascular disease at anytime after RA incidence (aHR 2.25; 95% CI 1.38-3.66) were significantly associated with an increased risk for dementia.

Study details: This was a retrospective cohort study including 886 patients with incident RA and without prior dementia, of which 103 patients developed dementia during a median follow-up of 8.5 years.

Disclosures: This study was supported by the US National Institutes of Health, National Institute of Aging, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. M Vassilaki reported receiving research funding and owning equity in various companies. MM Mielke reported receiving research grants or funding from and serving as a consultant for various sources.

Source: Kodishala C et al. Risk factors for dementia in patients with incident rheumatoid arthritis: A population-based cohort study. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.220200